# Critical Drug Interactions

## QT Prolongation Risk
Drugs that prolong QT interval — combining ≥2 increases risk of Torsades de Pointes:
- **Antiarrhythmics**: Amiodarone, sotalol, dofetilide, procainamide
- **Antibiotics**: Fluoroquinolones (moxifloxacin > levofloxacin), macrolides (azithromycin, erythromycin)
- **Antipsychotics**: Haloperidol, ziprasidone, quetiapine
- **Antidepressants**: Citalopram/escitalopram (dose-dependent), TCAs
- **Antiemetics**: Ondansetron (IV high dose), droperidol
- **Antifungals**: Fluconazole
- **Risk factors**: Hypokalemia, hypomagnesemia, bradycardia, female sex, structural heart disease
- **Monitoring**: Baseline ECG, correct electrolytes before starting, periodic ECG monitoring

## Serotonin Syndrome
Potentially fatal — caused by excess serotonergic activity:
- **High risk combinations**: MAOI + SSRI/SNRI (contraindicated, 14-day washout required)
- **Moderate risk**: SSRI + tramadol, SSRI + triptans, SSRI + linezolid, SSRI + methylene blue
- **Symptoms triad**: Mental status changes (agitation, confusion), autonomic instability (tachycardia, hyperthermia, diaphoresis), neuromuscular hyperactivity (clonus, hyperreflexia, tremor)
- **Treatment**: Discontinue offending agents, cyproheptadine, supportive care, benzodiazepines

## CYP450 Interactions
### CYP3A4 Inhibitors (increase levels of CYP3A4 substrates)
- Strong: Ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice
- Substrates affected: Statins (simvastatin, lovastatin — avoid combination), calcium channel blockers, calcineurin inhibitors, DOACs

### CYP3A4 Inducers (decrease levels of CYP3A4 substrates)
- Strong: Rifampin, carbamazepine, phenytoin, St. John's Wort
- Can reduce efficacy of: Oral contraceptives, DOACs, immunosuppressants, HIV medications

### CYP2D6 Inhibitors
- Strong: Fluoxetine, paroxetine, bupropion, quinidine
- Affect: Codeine (block conversion to morphine — reduced analgesia), tamoxifen (block conversion to endoxifen — reduced efficacy)

## Narrow Therapeutic Index Drugs — Require Careful Monitoring
- **Warfarin**: INR monitoring; numerous food/drug interactions
- **Digoxin**: Target 0.5-0.9 ng/mL; toxicity with hypokalemia, renal impairment; amiodarone increases levels 70-100%
- **Lithium**: Target 0.6-1.2 mEq/L; NSAIDs, ACEi, diuretics increase levels
- **Phenytoin**: Target 10-20 mcg/mL; zero-order kinetics — small dose changes cause large level changes
- **Theophylline**: Target 5-15 mcg/mL; CYP1A2 substrate (ciprofloxacin increases levels)
- **Aminoglycosides**: Nephrotoxicity and ototoxicity; monitor peaks and troughs

## Other Critical Interactions
- **Methotrexate + TMP-SMX**: Both antifolates — increased bone marrow suppression and toxicity
- **Potassium + ACEi + spironolactone**: Triple threat for hyperkalemia — monitor K+ closely
- **Clonidine + beta-blocker withdrawal**: Rebound hypertensive crisis
- **Sildenafil + nitrates**: Severe hypotension — contraindicated
- **Allopurinol + azathioprine/6-MP**: Allopurinol inhibits xanthine oxidase — reduce azathioprine dose by 75%
